KALVISTA PHARMACEUTICALS INCKALV
ASignal's systematic analysis rates KALV as Neutral.
Reflects the latest available analysis · analyzed Sep 16, 2026
The case on KALV
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.90)
- High gross margin (51.07%) indicating pricing power
- Current ratio of 5.17x and quick ratio of 4.97x showing strong liquidity
- Cash position exceeds total debt ($285.03M vs $284.31M)
- Positive sentiment from biotech-focused outlets like Pharmaceutical Technology and MT Newswires
- Negative operating cash flow (-$89.32M)
- Negative profit and operating margins (net margin: -118.74%, operating margin: -57.37%)
- EV/EBITDA of -10.38x indicating unprofitability
- High price-to-sales ratio (12.56x) relative to typical biotech benchmarks
- No Reddit retail sentiment data available
- Lack of revenue and earnings growth data (N/A)
See the full verdict on KALV
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes KALV
Most investors never get a second opinion, let alone several. ASignal runs KALV past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.